CryoLife, Inc. to Post Record Revenues for the Year 2001; FDA Approved BioGlue Shipped in December 2001

ATLANTA, Jan 3, 2002 /PRNewswire via COMTEX/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopedic grafts, and surgical adhesives, announced today that based upon early analysis of financial results, the Company expects revenues for the year ended December 31, 2001, to set a new record. CryoLife Inc. has achieved record revenues for 17 consecutive years.

Steven G. Anderson, President and Chief Executive Officer, CryoLife, Inc., noted, "The record revenues performance was partially attributed to BioGlue(R) surgical adhesive. Revenues for BioGlue, which continued to show substantial revenue increases, registered $3.1 million in the fourth quarter of 2001. The increase in BioGlue revenues includes initial shipments for vascular application as approved by the U.S. Food and Drug Administration (FDA) of the Company's Premarket Approval (PMA), as announced on December 4, 2001."

The CryoLife, Inc., audited financial results for the twelve-month period ended December 31, 2001, are scheduled to be released on Tuesday, January 29, 2002.

Founded in 1984, CryoLife, Inc. is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels and is CE marked in the European Community and approved in Canada and Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) heart valve, the SynerGraft vascular graft, the world's first tissue-engineered heart valve and vascular replacements, and the CryoLife-O'Brien(R) and CryoLife-Ross(R) stentless porcine heart valves, which are CE marked for distribution within the European Community. The human heart valves and vascular grafts processed by CryoLife using the SynerGraft technology are distributed in the U.S. under the trade names of CryoValve(R)SG and CryoVein(R)SG, respectively.

For additional information about the company, visit CryoLife's web site: http://www.cryolife.com .

    Contact:   D. Ashley Lee
               Vice President, Chief Financial Officer
               (800) 438-8285